// App-Quantinova.ai

Filters

Biomarkers











Conference Name











Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























1671 Abstracts

Efficacy and tolerability of nanoparticle docetaxel lipid suspension.

Aditya Murali - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

SYP-0709

Therapy selection and monitoring of early and late stage non small cell lung cancer (NSCLC) using a novel circulating tumor cells (CTCs) PD-L1 blood test.

Yen-Lin Chen - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Performance of two immunoafinity-based methods for CTC detection and molecular characterization in advanced colorectal cancer.

Santiago Cabezas-Camarero - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Dynamic variations in gene expressions of circulating tumor cells in metastatic castration-resistant prostate cancer patients in response to androgen receptor signaling inhibitors.

Yu Jen Jan - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Androgen Tear

Clinical utility of androgen-receptor splice variant 7 (AR-V7) determinations in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Danilo Piana - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Enzalutamide

Dendritic cell (DC) based cryoimmunotherapy (CryoIT) in a prospective phase I trial of metastatic castration resistant prostate cancer (mCRPC): Interim analysis.

Alfred Honore - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

N/A

Using administrative laboratory result data to describe adverse events.

Tamara P. Miller - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Prediction of chemotherapy related toxicities in older Asian adults with cancer.

Angela Pang - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Detection of endoglin-expressing CTCs in patients enrolled in an adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS).

Vinod Ravi - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pazopanib

Prospective serial sequencing of CTC/cfDNA and NK cell activity in patients undergoing multimodality treatment for triple negative breast cancer.

Hanna Irie - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Molecular analysis of thymidylate synthase in circulating tumor cells as a potential marker of response to therapy in locally advanced rectal cancer.

Virgilio Souza E Silva - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Applications of liquid biopsies as prognostic markers in patients (pts) with advanced ovarian cancer (AOC) on metronomic cyclophosphamide (MCy) with or without nintedanib (N) (Trans METRO-BIBF).

Marcia Hall - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

calcium/fluoride

Prognostic value of Mesenchymal Circulating Tumour Cells: Dynamic monitoring in patients with colorectal cancer.

Bin Xiong - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Role of circulating tumor cells by rare cell enumeration system in predicting response of non-small cell lung cancers to therapy.

Midhun Malla - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Clinical application of a novel CTC-chip to detect circulating tumor cells (CTCs) in malignant pleural mesothelioma (MPM).

Kazue Yoneda - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

CTCs enumeration and profile in different cancer types in a group of patients from the United States.

Dimitrios-Athanasios Ntanovasilis - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Quantification of circulating tumor cells as a biomarker for surveillance in oligometastatic patients after definitive radiation therapy.

Daniel Paul Lindsay - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Detection of androgen receptor expression in circulating tumor cells of metastatic breast cancer patients.

Tanja N. Fehm - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Androgen Tear

Correlation of circulating tumor cell phenotypes based on epithelial-mesenchymal transition with prognosis in first-line chemotherapy of HER2-negative metastatic breast cancer.

Xiuwen Guan - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

PD-L1 expression on circulating tumor cells in patients with hepatocellular carcinoma.

Hee Yeon Kim - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved